Behnam Badie, M.D., F.A.C.S.

  • Vice Chair and Professor, Department of Surgery
  • Chief, Division of Neurosurgery
  • Director, Brain Tumor Program
  • Neurosurgeon

Behnam Badie, M.D., F.A.C.S.

Enfoque de la investigación :
  • Neurologic oncology
  • Brain tumor immunology
  • Development of minimally invasive techniques for treatment of both benign and malignant brain tumors
Especialidades clínicas
  • Neurosurgery
Áreas de especialidad
  • Surgical neuro-oncology
  • Skull base tumors
  • Acoustic neuromas
  • Pituitary tumors
  • Meningiomas and other nervous system tumors
Ayuda disponible en varios idiomas
  • Farsi

“I love taking care of patients. It's a privilege for me...  for patients to trust me with their care.”

After 20 years and thousands of brain surgeries at the University of Wisconsin, Madison, Behnam Badie, M.D., joined City of Hope in 2005 because he wanted to have an even greater impact.

“Being a neurosurgeon is not enough. It has to be through science and technology. And that’s one of the reasons I came to City of Hope.”

Dr. Badie, an expert in the field of surgical neuro-oncology, a University California, Los Angeles-trained surgeon and our Brain Tumor Program and Chief of Neurosurgery is leading groundbreaking research into nanotechnology as a tool for delivering cancer-fighting drugs directly into tumors, in a minimally invasive manner.

Winner of a long list of awards and honors, Dr. Badie says his entire perspective on surgery changed when his father died of a brain tumor. “It has really helped me get closer to my patients,” he says.

 

  • July 2011 - Present, Beckman Research Institute Board of Directors Beckman Research Institute of City of Hope, Duarte, CA
  • May 2011-present Vice Chair, Department of Surgery City of Hope Medical Center Duarte, CA
  • June, 2012- present- Chair, Faculty Senate Executive Committee Beckman Research Institute/City of Hope Medical Center, Duarte CA
  • 2005 - present, Professor, Chief, Division of Neurosurgery, City of Hope, Duarte, CA
  • August 2005 - December 2009 Associate Professor, Chief Division of Neurosurgery, City of Hope Medical Center Duarte, CA
  • 2005 - present, Director, Brain Tumor Program, City of Hope, Duarte, CA
  • 2004 - 2005, Member, Cellular and Molecular Pathology Training Program, University of Wisconsin, Madison
  • 2003 - 2005, Vice-Chair, Academic Affairs, Department of Neurological Surgery, University of Wisconsin, Madison
  • 2002 - 2005, Associate Professor (Tenure), Department of Neurological Surgery, University of Wisconsin, Madison
  • 1996 - 2005, Member, University of Wisconsin Comprehensive Cancer Center, Immunology/Biological Therapy Program
  • 1996 - 2005, Member, University of Wisconsin Comprehensive Cancer Center, Immunology/Biological Therapy Program
  • 1996 - 2005, Director, Comprehensive Brain Tumor Program. University of Wisconsin, Madison
  • 1996 - 2002, Assistant Professor, Department of Neurological Surgery. University of Wisconsin, Madison

Títulos

  • 1985 -1989 - University of California School of Medicine, Los Angeles, CA, M.D.
  • 1980 -1984, University of California Los Angeles, Division of Biochemistry, B.S.

Residencia

  • 1990 -1996, University of California Los Angeles, Division of Neurological Surgery, Resident

Pasantía

  • 1989 -1990, University of California Los Angeles, Department of Surgery, Intern

Dr. Badie’s research interests focus on brain tumor immunology. More specifically, his research team is attempting to develop novel immunotherapy approaches for malignant brain tumors through the activation of microglia and macrophages using nanoparticles. This research is currently funded by the NCI and other organizations.

IMMUNOTHERAPY

Nanotubes: Small and Lethal Envelopes Used to Kill Cancer

Nanotubes are microscopic technology shaped into tiny tubes about 1/10,000th the width of a human hair.  Behnam Badie, M.D., is working closely with Jacob Berlin, Ph.D., to use nanotubes to deliver a drug called CpG, which activates immune cells called macrophages to recognize and attack tumor cells. Because nanotubes can carry the drug directly to macrophages around the tumor, patients can receive stronger dosages, tolerate their therapy better and recover more quickly.

Principal investigators: Behnam Badie, M.D.; Jacob Berlin, Ph.D. and Leying (Larry) Zhang, Ph.D.

Nanoparticles: Guiding Cancer Treatment to the Tumor with Magnets

Behnam Badie, M.D., is collaborating with scientists at Caltech to design a dynamically programmable, low-intensity magnetic field to route and traffic macrophages that have been treated with CpG to tumor sites. In this method, patients would receive CpG-loaded nanoparticles engineered with an iron oxide, so that the macrophages become magnetic.  The magnetic field is generated by a grid, which allows for control over the spatial and temporal profile. Dr. Badie believes that directing CpG-treated macrophages to the areas where they are needed will make this treatment approach even more effective and durable.

Principal investigator: Behnam Badie, M.D.

Macrophages and Microglia: Harnessing the Immune System's Clean-up Crew

Macrophages are immune cells that act as scavengers feeding upon dead cells, foreign substances, and other debris in the body. Microglia are macrophages specific to the central nervous system. Microglia are normally inactive but become activated in response to inflammation, infection and trauma. Once activated, they proliferate and migrate to the site of injury. Behnam Badie, M.D., is researching ways to improve outcomes in post-surgical brain tumor patients by re-engineering the microglia to deliver therapeutic agents to the tumor site, killing residual tumor cells. He also aims to extend the life of T cells using microglia and test their efficacy against cancer. This study will likely garner results within a year, setting the stage for Phase I clinical trials.

Principal investigators: Behnam Badie, M.D. , and Leying (Larry) Zhang, Ph.D.

GENE THERAPY

Creating an Innovative Approach to Therapy

Macrophages are plentiful around tumor sites; however, they aid tumor growth instead of mounting an immune attack.  Behnam Badie, M.D., has found that these tumor-associated macrophages express high levels of an enzyme that inhibits the attack of T cells, the next line of immune response, and he has devised a pioneering concept to use tumor-associated macrophages to deliver genetic material to tumors.

The first step is a bone marrow transplant to remove the patient’s existing immune system and replace it with white blood cells that give rise to new modified macrophages. These macrophages are engineered with an inactive gene, which needs a promoter to become active. The modified macrophage will still respond to the tumor’s manipulation by traveling to the tumor site and secreting proteins that stimulate tumor growth. These proteins are the “promoters” that activate the genetic material.

At the same time, the patient is administered a prodrug, which is inactive. The activated gene makes material that converts the prodrug into active chemotherapy — which kills tumor cells. Meanwhile, that same active genetic material induces suicide in macrophages, so that they can no longer be employed for tumor growth. And because these modified macrophages are born from the new white blood cells, if the tumor reappears, the new macrophages will halt new tumor growth.

Principal Investigator: Behnam Badie, M.D.

MINIMALLY INVASIVE APPROACHES

Designing Leading-Edge Technology for Delivering Targeted Treatment

Behnam Badie, M.D., has designed a minimally invasive technique to debulk and treat brain tumors without open surgery – making treatment more effective while reducing trauma, the amount of drug used and time involved. The technique involves Badie inserting into the tumor a narrow cylinder, through which a small instrument reaches in and debulks it. The result is a reservoir in the center of the tumor into which a small tube is inserted and left just under the scalp to inject large amounts of targeted therapy.

Principal investigator: Behnam Badie, M.D.

CHEMOTHERAPY

Uncovering New Targets for Treatment

Macrophages are a first line of immune defense. They detect foreign debris, like bacteria and viruses, and present the proteins from these invaders to T cells, another type of immune cell that then mounts a coordinated attack. Brain tumor cells evade this response and more – they manipulate macrophages to work for them by supplying the tumor with oxygen and nutrients. Macrophages found around tumor cells also secrete proteins that encourage tumor cell growth.

Behnam Badie, M.D., and his team are researching new therapies to fight or reverse this manipulated response. They have found a protein secreted by tumor cells called S100B, which they believe plays a feature role in cancer’s ability to attract and subvert macrophages, and they are now working with City of Hope’s High Throughput Screening Core to identify lead compounds that inhibit S100B.

Principal investigator: Behnam Badie, M.D.

The Future of Brain Surgery and Research
The Future of Brain Surgery and Research

The Future of Brain Surgery and Research

28 de agosto de 2015
  • American Association for the Advancement of Science
  • American Association for Cancer Research
  • American Association of Neurological Surgeons (AANS)
  • American Society of Gene Therapy
  • Congress of Neurological Surgeons (CNS)Society of Neuro-oncology
  • International Society for Biological Therapy of Cancer
  • North American Skull Base Society
  • Western Neurosurgical Society
  • 2012 Caltech-City of Hope Biomedical Initiative Award Recipient
  • 2011 City of Hope Excellence Award Winner
  • 2007- 2012, "Americas Top Doctors for Cancer" by Castle Connolly
  • 2008, "Top Doctors for Cancer" by Castle Connolly
  • 2007, Courage and Dedication Crystal Award, International Brain Mapping and Intra-operative Surgical Planning Society (IBMISPS)
  • 2007, "Top Doctors for Cancer" by Castle Connolly
  • 2002, Departmental Teaching Award in Neurosurgery, University of Wisconsin, Alpha Omega Alpha Medical Society
  • 1988, Howard Hughes Medical Student Research Grant Summer 1987
  • 2003 - 2004, Best Doctors in America
  • Alpha Omega Alpha Magna Cum Laude Departmental Honors in Biochemistry
  • 2002, Best abstract presentation, AANS/CNS Section on Tumors
  • 2002, Magna Cum Laude and Excellence in Design for education exhibit, The Radiological Society of North America
  • 2002, "Top Doctor" or "Best Doctor" by Castle Connolly and/or BestDoctors.com
  • 1986, Best abstract presentation, Medical Student Summer Research Program
  • 1984
  • Magna cum Laude , UCLA Departmental Honors in Biochemistry
Ir al Inicio